Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06391099 · ClinicalTrials.gov registry record · NA
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
A NA study of Metastatic Renal Cell Carcinoma and Clinical Stage IV Cutaneous Melanoma AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06391099: Recruiting NA study of Metastatic Renal Cell Carcinoma and Clinical Stage IV Cutaneous Melanoma AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center.
NCT06391099 is a NA study of Metastatic Renal Cell Carcinoma and Clinical Stage IV Cutaneous Melanoma AJCC v8 that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 60 participants, below the 142-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06391099, a NA study of Metastatic Renal Cell Carcinoma and Clinical Stage IV Cutaneous Melanoma AJCC v8, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies how well a ketogenic dietary intervention works to improve response to immunotherapy in patients with melanoma and kidney cancer that has spread from where it first started (primary site) to other places in the body (metastatic). A ketogenic diet (KD) means eating fewer carbohydrates and more fats. The purpose is to use ketones (normal breakdown from fat) instead of glucose (sugar) as an energy source. Researchers want to see whether a ketogenic diet can improve tumor response in patients receiving immune checkpoint inhibitors (ICI). ICI are newer treatment options that help the immune system better fight some cancers. Following a KD may improve tumor response in patients with metastatic melanoma and metastatic kidney cancer treated with ICI.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- OTHER Best Practice
- OTHER Dietary Intervention
- OTHER Educational Activity
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06391099 shows while recruiting
NCT06391099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 142-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (58% lower).
The record links to 4 conditions, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06391099 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06391099 about?
NCT06391099 is a clinical study titled "Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer". This phase I trial studies how well a ketogenic dietary intervention works to improve response to immunotherapy in patients with melanoma and kidney cancer that has spread from where it first started (primary site) to other places in the body (metastatic). A ketogenic diet (KD) means eating fewer ca...
What is the current status of trial NCT06391099?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-11-17. Estimated completion is 2027-12-31.
What conditions does trial NCT06391099 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Metastatic Cutaneous Melanoma.
What interventions are being tested in trial NCT06391099?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Best Practice (OTHER), Dietary Intervention (OTHER), Educational Activity (OTHER).
Who is sponsoring clinical trial NCT06391099?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06391099 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06391099's enrollment target sits among peer trials
60 19th of 37 higher than 18 of 37 other Metastatic Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer
ACTIVE NOT RECRUITING · NA
-
Cancer and Blood Pressure Management, CARISMA Study
ACTIVE NOT RECRUITING · NA
-
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
COMPLETED · NA
-
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
COMPLETED · NA
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI